Agranulocytosis, acquired
Agranulocytosis, acquired is rated under 38 CFR 38 CFR § 4.117, Diagnostic Code 7702, from 10% to 100% based on the frequency and functional severity of symptoms. The maximum 100% rating requires: Requiring bone marrow transplant; or infections recurring, on average, at least once every six weeks per 12-month period. Most claims establish the 10% or 30% rating before reaching the top tier.
Rating schedule — DC 7702 at a glance
- Minimum rating
- 10%
- Maximum rating
- 100%
- Rating tiers
- 4
- CFR section
- 38 CFR § 4.117
- Body system
- Hematologic & Lymphatic System
- Secondary conditions
- 0
Lowest schedular rating available
Full schedular disability
10%, 30%, 60%, 100%
Part 4 rating schedule
None mapped
What are the VA rating criteria for Agranulocytosis, acquired?
Requiring continuous medication (e.g., antibiotics) for control; or requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/µl
Requiring intermittent myeloid growth factors to maintain ANC greater than 1000/µl; or infections recurring, on average, at least once per 12-month period but less than once every three months per 12-month period
Requiring intermittent myeloid growth factors (granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or continuous immunosuppressive therapy such as cyclosporine to maintain absolute neutrophil count (ANC) greater than 500/microliter (µl) but less than 1000/µl; or infections recurring, on average, at least once every three months per 12-month period
Requiring bone marrow transplant; or infections recurring, on average, at least once every six weeks per 12-month period
“Requiring intermittent myeloid growth factors (granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or continuous immunosuppressive therapy such as cyclosporine to maintain absolute neutrophil count (ANC) greater than 500/microliter (µl) but less than 1000/µl; or infections recurring, on average, at least once every three months per 12-month period”
Common Questions About Agranulocytosis, acquired VA Ratings
What is the VA rating range for Agranulocytosis, acquired?
The VA rates Agranulocytosis, acquired under Diagnostic Code 7702 at 10%, 30%, 60%, 100%. The minimum 10% rating requires: Requiring continuous medication (e.g., antibiotics) for control; or requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/µl. The maximum 100% rating requires: Requiring bone marrow transplant; or infections recurring, on average, at least once every six weeks per 12-month period.
Which 38 CFR diagnostic code does the VA use for Agranulocytosis, acquired?
The VA rates Agranulocytosis, acquired under Diagnostic Code (DC) 7702, governed by 38 CFR 38 CFR § 4.117. The diagnostic code establishes the specific rating tiers and severity criteria the VA examiner applies.
What is the difference between a 10% and a 100% rating for Agranulocytosis, acquired?
A 10% rating requires: Requiring continuous medication (e.g., antibiotics) for control; or requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/µl. A 100% rating requires: Requiring bone marrow transplant; or infections recurring, on average, at least once every six weeks per 12-month period. The difference typically reflects the frequency, severity, or functional impact of the condition as documented in medical records and C&P examination findings.
Can Agranulocytosis, acquired qualify for TDIU (Total Disability Individual Unemployability)?
Veterans rated for Agranulocytosis, acquired may qualify for TDIU if the condition — alone or in combination with other service-connected disabilities — prevents substantially gainful employment. A single disability rated at 60% or higher (or multiple disabilities combining to 70%, with one at 40%) can support a TDIU claim under 38 CFR § 4.16.
What evidence do I need to establish service connection for Agranulocytosis, acquired?
Service connection for Agranulocytosis, acquired requires three elements: (1) a current diagnosis of the condition, (2) an in-service event, injury, or disease, and (3) a medical nexus linking the current diagnosis to that in-service occurrence. A nexus letter from a treating or independent medical examiner is the most reliable nexus evidence.
What is the C&P exam like for Agranulocytosis, acquired?
A Compensation & Pension (C&P) exam for Agranulocytosis, acquired uses a Disability Benefits Questionnaire (DBQ) specific to the body system involved. The examiner documents the frequency, severity, and functional impact of your symptoms. Bring all relevant treatment records and be prepared to describe your worst-day symptoms — the examiner rates your condition based on the full clinical picture, not a single visit.
Get a Personalized Rating Analysis
VeteranHQ evaluates your symptoms against the exact 38 CFR criteria, identifies secondary conditions, and shows what evidence you need to support a higher rating.
Discover Your Benefits